Scottsdale, United States
Systems Oncology, founded in 2015, is redefining treatment paradigms in the biotechnology and healthcare sectors with its innovative multimodal RNA therapeutics. Headquartered in the United States, the company is focused on disrupting traditional approaches to combat complex diseases with its cutting-edge technologies.
Under their slogan, "Deeper Insights, Multimodal Drugs - We translate genomic intelligence into multi-targeting therapies," Systems Oncology leverages its proprietary Arromer platform to design self-delivering RNA molecules. These are engineered to silence multiple disease targets simultaneously, providing enhanced precision in targeting specific tissues while addressing challenges like emerging drug resistance.
The company is initially concentrating on oncology, but its versatile RNA platform holds potential across various polygenic diseases. While Systems Oncology has yet to announce its latest investment round, its focus on developing a robust product pipeline indicates a promising opportunity for investors within the intersecting realms of biotechnology and health care.
